Ticker >

Murae Organisor share price

Murae Organisor Ltd.

BSE: 542724 SECTOR: Pharmaceuticals & Drugs  25k   29   3

1.43
-0.07 (-4.67%)
BSE: 28 Mar 4:00 PM

Price Summary

Today's High

₹ 1.43

Today's Low

₹ 1.43

52 Week High

₹ 3.1

52 Week Low

₹ 0.9

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

35.34 Cr.

Enterprise Value

44.05 Cr.

No. of Shares

24.71 Cr.

P/E

0

P/B

0.65

Face Value

₹ 2

Div. Yield

0 %

Book Value (TTM)

₹  2.21

CASH

0.03 Cr.

DEBT

8.74 Cr.

Promoter Holding

0 %

EPS (TTM)

₹  -0.03

Sales Growth

-33.01%

ROE

11.18 %

ROCE

11.66%

Profit Growth

-10.92 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-33.01%
3 Year-36.53%
5 Year-16.84%

Profit Growth

1 Year-10.92%
3 Year2.96%
5 Year16.73%

ROE%

1 Year11.18%
3 Year8.68%
5 Year15.21%

ROCE %

1 Year11.66%
3 Year9.41%
5 Year13.92%

Debt/Equity

0.4672

Price to Cash Flow

134.62

Interest Cover Ratio

10.6253443526171

CFO/PAT (5 Yr. Avg.)

0

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Dec 2023 0 0
Sep 2023 0 0
Jun 2023 0 0
Mar 2023 0 0
Dec 2022 0 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy liquidity position with current ratio of 2.84875789302981.

 Limitations

  • The company has shown a poor profit growth of 2.95986995476867% for the Past 3 years.
  • The company has shown a poor revenue growth of -36.526727314164% for the Past 3 years.
  • Company has high debtor days of 303.456998403406.
  • The company has a low EBITDA margin of -4.91486673912663% over the past 5 years.
  • The company is trading at a high EV/EBITDA of 122.0418.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 1.17 1.53 1.71 0.43 0.4
Total Expenditure 1.03 0.33 2.38 1.38 0.35
Operating Profit 0.14 1.21 -0.66 -0.95 0.06
Other Income 1.4 0 0.66 0 0
Interest 0.14 0.15 0.26 0.01 0
Depreciation 0.03 0.03 0.02 0.02 0.02
Exceptional Items 0 0 0 0 0
Profit Before Tax 1.37 1.03 -0.28 -0.98 0.04
Tax 0 0.77 0 -0.11 0
Profit After Tax 1.37 0.26 -0.28 -0.87 0.04
Adjusted EPS (Rs) 0.19 0.04 -0.01 -0.04 0

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 50.7 55.11 41.08 21.04 14.09
Total Expenditure 47.4 53.87 48.84 25.46 13.17
Operating Profit 3.3 1.24 -7.76 -4.42 0.93
Other Income 0.05 2.27 8.93 7.7 2.26
Interest 1.04 0.97 0.93 0.08 0.29
Depreciation 0.04 0.1 0.12 0.12 0.1
Exceptional Items 0 0 0 0 0
Profit Before Tax 2.28 2.45 0.12 3.08 2.8
Tax 0.62 0.63 0.03 0.86 0.81
Net Profit 1.66 1.82 0.09 2.22 1.98
Adjusted EPS (Rs.) 0.33 0.25 0.01 0.3 0.27

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 0.31 6.17 6.17 12.34 12.34
Total Reserves 5.64 8.25 8.33 4.39 6.37
Borrowings 2.59 1.37 2.38 0 0
Other N/C liabilities 0.01 0.01 0.01 0.01 0.01
Current liabilities 14.71 20.36 10.98 12.06 9.87
Total Liabilities 23.26 36.16 27.87 28.79 28.58
Assets
Net Block 0.48 0.8 0.76 0.58 0.48
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 3.03 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 22.78 32.33 27.11 28.21 28.11
Total Assets 23.26 36.16 27.87 28.79 28.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 2.28 2.45 0.12 3.08 2.8
Adjustment 1.08 1.07 1.05 0.2 0.39
Changes in Assets & Liabilities -2.18 -5.36 -7.31 0.18 -2.11
Tax Paid -0.62 -0.63 -0.03 -0.86 -0.81
Operating Cash Flow -0.48 -3.45 -7.1 2.61 0.26
Investing Cash Flow -0.32 -3.45 2.94 0.06 0
Financing Cash Flow 0.94 6.76 2.9 -2.67 -0.29
Net Cash Flow 0.14 -0.14 -1.26 -0.01 -0.03

Corporate Actions

Investors Details

PARTICULARS Jun 2021% Sep 2021% Dec 2021% Mar 2022% Jun 2022%
promoters 70.04 70.04 70.04 50.21 37.57
bhumishth narendrabhai pa... 28.39 28.39 28.39 18.10 11.97
narendrakumar gangaramdas... 6.62 6.62 6.62 5.06 3.36
payal bhumishth patel 28.39 28.39 28.39 23.09 20.16
sushilaben narendrakumar ... 6.62 6.62 6.62 3.96 2.09
PARTICULARS Dec 2022% Mar 2023% Jun 2023% Sep 2023% Dec 2023%
investors 100.00 100.00 100.00 100.00 100.00
ashok kumar chaudhary - - - 1.03 1.03
riaz khan 2.90 4.40 1.68 2.83 2.83
tapan kumar sarkar - - - 1.40 1.01
dhwanil saumil bhavnagari... - - 12.14 1.15 -
amrapali capital and fina... - - 8.05 - -
nimit jayendrabhai shah - - 11.82 - -
nirav m kothari - - 4.05 - -
rajesh nanubhai jhaveri - - 11.73 - -
saumil a bhavnagari - - 12.14 - -
vicky r. jhaveri - - 10.35 - -

Annual Reports

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Earum Pharmaceutical - Quaterly Results14 Feb 2024, 6:05PM Earum Pharmaceuticals informs about board meeting17 Jan 2024, 5:25PM Earum Pharmaceutical - Quaterly Results9 Dec 2023, 4:43PM Earum Pharmaceutical - Quaterly Results9 Dec 2023, 4:43PM Earum Pharmaceutical - Quaterly Results9 Dec 2023, 4:43PM Earum Pharmaceuticals informs about record date23 Sep 2023, 12:13PM Earum Pharmaceuticals informs about resignation of CFO9 Aug 2023, 5:00PM Earum Pharmaceuticals informs about disclosure 7 Jul 2023, 2:56PM Earum Pharmaceuticals informs about board meeting 27 Jun 2023, 10:40AM Earum Pharmaceuticals informs about disclosure5 Jun 2023, 12:32PM Earum Pharmaceuticals submits board meeting intimation10 May 2023, 1:11PM Earum Pharmaceuticals informs about outcome of board meeting19 Apr 2023, 4:19PM Earum Pharmaceutical - Quaterly Results10 Feb 2023, 4:48PM Earum Pharmaceutical - Quaterly Results10 Feb 2023, 4:48PM Earum Pharmaceuticals informs about EGM 11 Jan 2023, 12:50PM Earum Pharmaceutical - Quaterly Results5 Nov 2022, 4:00PM Earum Pharmaceutical - Quaterly Results5 Nov 2022, 4:00PM Earum Pharmaceutical - Quaterly Results5 Nov 2022, 4:00PM Earum Pharmaceuticals informs about disclosure 25 Aug 2022, 12:16PM Earum Pharmaceuticals informs about disclosure20 Aug 2022, 12:51PM Earum Pharmaceuticals informs about press release12 Aug 2022, 4:30PM Earum Pharmaceuticals informs about book closure8 Aug 2022, 12:42PM Earum Pharmaceuticals informs about disclosure5 Aug 2022, 4:16PM Earum Pharmaceuticals informs about disclosure 23 Jul 2022, 3:44PM Earum Pharmaceuticals informs about disclosure23 Jul 2022, 3:41PM Earum Pharmaceuticals informs about disclosures 22 Jul 2022, 4:04PM Earum Pharmaceuticals informs about disclosure21 Jul 2022, 4:22PM Earum Pharmaceuticals informs about disclosure20 Jul 2022, 5:00PM Earum Pharmaceuticals informs about disclosure 20 Jul 2022, 5:00PM Earum Pharmaceutical - Quaterly Results14 Jul 2022, 5:27PM Earum Pharmaceutical - Quaterly Results14 Jul 2022, 5:27PM Earum Pharmaceutical - Quaterly Results14 Jul 2022, 5:27PM Earum Pharmaceuticals informs about disclosure24 Jun 2022, 2:35PM Earum Pharmaceuticals informs about annual secretarial compliance report13 Jun 2022, 5:00PM Earum Pharmaceuticals informs about resignation of director10 Jun 2022, 5:19PM Earum Pharmaceuticals informs about disclosure27 Apr 2022, 11:13AM Earum Pharmaceuticals informs about disclosure27 Apr 2022, 11:12AM Earum Pharmaceuticals informs about disclosure22 Apr 2022, 3:23PM Earum Pharmaceuticals informs about disclosure22 Apr 2022, 10:11AM Earum Pharmaceutical - Quaterly Results18 Apr 2022, 4:48PM Earum Pharmaceutical - Quaterly Results18 Apr 2022, 4:48PM Earum Pharmaceutical - Quaterly Results18 Apr 2022, 4:48PM Earum Pharmaceuticals informs about disclosure11 Mar 2022, 9:29AM Earum Pharmaceuticals informs about disclosure11 Mar 2022, 9:28AM Earum Pharmaceuticals informs about disclosure19 Jan 2022, 3:34PM Earum Pharmaceutical - Quaterly Results11 Jan 2022, 1:12PM Earum Pharmaceutical - Quaterly Results11 Jan 2022, 1:12PM Earum Pharmaceutical - Quaterly Results11 Jan 2022, 1:12PM Earum Pharmaceuticals inks digital MoU with Government of Gujarat4 Jan 2022, 9:34AM Earum Pharmaceuticals informs about record date30 Nov 2021, 9:50AM

Murae Organisor Stock Price Analysis and Quick Research Report. Is Murae Organisor an attractive stock to invest in?

 

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Murae Organisor and its performance over the period of time.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Murae Organisor cash from the operating activity was Rs 0.2625 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Murae Organisor has a Debt to Equity ratio of 0.4672 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Murae Organisor , the EPS growth was -10.9251968503937 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Murae Organisor has OPM of 6.57796700372538 % which is a bad sign for profitability.
     
  • ROE: Murae Organisor have a average ROE of 11.1831744365231 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Murae Organisor is Rs 1.43. One can use valuation calculators of ticker to know if Murae Organisor share price is undervalued or overvalued.
Last Updated on:
Brief about Murae Organisor
X